(Q37612683)

21 August 2017

1 reference

title

Recognizing ADHD in adults with comorbid mood disorders: implications for identification and management (English)

1 reference

21 August 2017

1 reference

David W Goodman

1

1 reference

PubMed ID

19820271

21 August 2017

Michael E Thase

series ordinal

2

1 reference

PubMed ID

19820271

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

21 August 2017

Postgraduate Medicine

1 reference

21 August 2017

121

1 reference

21 August 2017

20-30

1 reference

21 August 2017

5

1 reference

Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report

21 August 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Attention-deficit/hyperactivity disorder in adults: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Molecular genetics of attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

The consequences of attention-deficit/hyperactivity disorder in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Trends in medication treatment for ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Young adults with attention deficit hyperactivity disorder: subtype differences in comorbidity, educational, and clinical history.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

A comparison of service use and costs among adults with ADHD and adults with other chronic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Development of a new psychosocial treatment for adult ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2049

21 January 2018

Identifiers

DOI

10.3810/PGM.2009.09.2049

1 reference

21 August 2017

1 reference

PubMed ID

19820271